Literature DB >> 17275269

Increased tumor localization and reduced immune response to adenoviral vector formulated with the liposome DDAB/DOPE.

Jason C Steel1, Heather M A Cavanagh, Mark A Burton, Mones S Abu-Asab, Maria Tsokos, John C Morris, Wouter H J Kalle.   

Abstract

UNLABELLED: We aimed to increase the efficiency of adenoviral vectors by limiting adenoviral spread from the target site and reducing unwanted host immune responses to the vector. We complexed adenoviral vectors with DDAB-DOPE liposomes to form adenovirus-liposomal (AL) complexes. AL complexes were delivered by intratumoral injection in an immunocompetent subcutaneous rat tumor model and the immunogenicity of the AL complexes and the expression efficiency in the tumor and other organs was examined. Animals treated with the AL complexes had significantly lower levels of beta-galactosidase expression in systemic tissues compared to animals treated with the naked adenovirus (NA) (P<0.05). The tumor to non-tumor ratio of beta-galactosidase marker expression was significantly higher for the AL complex treated animals. NA induced significantly higher titers of adenoviral-specific antibodies compared to the AL complexes (P<0.05). The AL complexes provided protection (immunoshielding) to the adenovirus from neutralizing antibody. Forty-seven percent more beta-galactosidase expression was detected following intratumoral injection with AL complexes compared to the NA in animals pre-immunized with adenovirus.
CONCLUSIONS: Complexing of adenovirus with liposomes provides a simple method to enhance tumor localization of the vector, decrease the immunogenicity of adenovirus, and provide protection of the virus from pre-existing neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17275269     DOI: 10.1016/j.ejps.2006.12.004

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  3 in total

1.  Multiple treatment cycles of liposome-encapsulated adenoviral RIP-TK gene therapy effectively ablate human pancreatic cancer cells in SCID mice.

Authors:  Shi-He Liu; Nancy Smyth-Templeton; Alan R Davis; Elizabeth A Davis; Nikiforos Ballian; Min Li; Hao Liu; William Fisher; F Charles Brunicardi
Journal:  Surgery       Date:  2011-02-05       Impact factor: 3.982

2.  Co-delivery of adenovirus and carmustine by anionic liposomes with synergistic anti-tumor effects.

Authors:  Zhirong Zhong; Yu Wan; Sanjun Shi; Jianfeng Han; Zhirong Zhang; Xun Sun
Journal:  Pharm Res       Date:  2011-07-26       Impact factor: 4.200

3.  Increasing the efficacy of oncolytic adenovirus vectors.

Authors:  Karoly Toth; William S M Wold
Journal:  Viruses       Date:  2010-08-27       Impact factor: 5.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.